Moderna sees 5-year follow up from Phase 2 study in 2026

Moderna (MRNA) shares dropped 4.2% to $25.99 on Friday afternoon after the company provided an update on mRNA-4359 plus pembrolizumab at an oncology event. The company said that the five-year follow up from the Phase 2 study comparing mRNA-4157/V940 in combination with KEYTRUDA to KEYTRUDA alone in adjuvant melanoma is expected in 2026. At a median planned follow-up of the Phase 2 study at 34.9 months, mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 49%. The recurrence free survival rate of mRNA-4157/V940 in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone, at ~3 years of follow-up, Moderna said, adding that At ~ 3 years of follow-up, mRNA-4157/V940 in combination with KEYTRUDA also continued to demonstrate a meaningful improvement in distant metastasis-free survival compared with KEYTRUDA alone, reducing the risk of developing distant metastasis or death by 62%, and that mRNA-4157/V940 in combination with KEYTRUDA was well tolerated without potentiation of immune-related adverse events compared to KEYTRUDA alone. The Phase 3 trial is fully enrolled, Moderna said.